MoonLake Immunotherapeutics (MLTX) Common Equity (2020 - 2026)

MoonLake Immunotherapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $254.0 million for Q1 2026.

• On a quarterly basis, Common Equity fell 38.43% year-over-year to $254.0 million in Q1 2026; TTM through Mar 2026 was $254.0 million, a 38.43% decrease from a year earlier, with the FY2025 full-year figure at $304.5 million, down 32.84% from the prior year.
• Common Equity fell to $254.0 million in Q1 2026 per MLTX's latest filing, from $304.5 million in the prior quarter.
• Across five years, Common Equity topped out at $552.4 million in Q1 2024 and bottomed at -$25.3 million in Q1 2022.
• The 5-year median for Common Equity is $357.9 million (2025), against an average of $319.6 million.
• Biggest YoY gain for Common Equity was 11310.99% in 2022; the steepest drop was 10205.8% in 2022.
• Year by year, Common Equity stood at $68.8 million in 2022, then jumped by 646.71% to $513.5 million in 2023, then slipped by 11.7% to $453.4 million in 2024, then plunged by 32.84% to $304.5 million in 2025, then dropped by 16.57% to $254.0 million in 2026.
• Per Business Quant, the three latest MLTX Common Equity figures stand at $254.0 million (Q1 2026), $304.5 million (Q4 2025), and $291.2 million (Q3 2025).